Shares of Hims & Hers Health tumbled 8.9% to €26.24 after Bloomberg reported that Visa placed the telehealth company in its Acquirer Monitoring Program following a surge of customer credit-card disputes in its weight-loss subscription business in July. The penalty itself is small, but the signal it sends about the company's billing model — the engine behind nearly 3 million subscribers — is not.
$75,000 Is Pocket Change; the Real Cost Is What Comes Next. Visa will add an $8 fee per dispute, totaling nearly $75,000 for September. That's negligible against $753 million in quarterly revenue. But to exit the monitoring program, Hims must push its dispute rate below 1.5% of transactions for three consecutive months.
That typically forces subscription businesses to overhaul how they sell and bill: clearer pricing screens, more explicit renewal terms, faster refunds, and tighter checks at sign-up. Each of those changes risks slowing new sign-ups or accelerating cancellations — directly threatening the subscriber growth investors have been paying up for.
Margins Were Already Sliding Before the Visa Flag. This arrives at the worst possible moment. Gross margin fell to 64% in Q2, down from 76% a year earlier — a fourth consecutive quarterly decline — as branded weight-loss drugs carry thinner profits. Hims swung to a loss of $86.3 million, from a $42.5 million profit the year before.
Barclays trimmed its price target on the stock to $35 from $39 on August 21 , reflecting concern that billing friction compounds margin pressure at the same time.
A Widening Legal Cloud Makes the Picture Murkier. Berger Montague has launched an investigation into the board, focused on whether Hims improperly shared private health data with advertisers, used deceptive billing practices, and made subscription cancellations unnecessarily difficult.
Q2 results already included $81 million in one-time costs covering restructuring and legal reserves tied to FTC litigation. The Visa dispute data could hand regulators and plaintiffs' lawyers a fresh data point.
The Company Insists Its Checkout Is Transparent — Customers Disagree. A spokesperson said the company has "built a checkout process that is clear about the cost of a Hims & Hers membership and any medication a provider chooses to prescribe." But BBB complaints describe customers being silently moved from grandfathered plans to $149/month memberships without disclosure — a pattern Hims itself acknowledged in writing. When the payment network sees the same friction that consumers and regulators do, it becomes harder to dismiss as isolated noise.